Doseology Sciences Inc. develops consumer products around precision-controlled oral stimulant pouch technologies. News about Doseology Sciences centers on its non-nicotine, caffeine-based Feed That Brain Energy Pouches, direct-to-consumer distribution in the United States, pilot production, brand development, and the use of oral pouch formats for controlled stimulant delivery.
Company updates also cover OTCQB trading under DOSEF, capital-markets communications, governance changes, and regulatory strategy for oral pouch products, including formulation, data generation, PMTA preparation, and post-market compliance themes tied to regulated consumer stimulant categories.
Doseology Sciences (OTCQB: DOSEF) announced the revocation of its management cease trade order and plans to adopt semi-annual financial reporting. The British Columbia Securities Commission revoked the order issued October 29, 2026, after Doseology filed its required annual disclosures on November 3, 2026, for the fiscal year ended June 30, 2026. The company is no longer listed as in default in its Canadian reporting jurisdictions that maintain such lists.
Under the Semi-Annual Reporting Pilot Program, Doseology will skip interim statements and related management discussion for the periods ending September 30, 2026, and March 31, 2027, and subsequent three- and nine-month periods. Audited annual statements and six-month interim reports will continue. Doseology confirms it meets the eligibility criteria and aims to reduce reporting costs and administrative work. Material-change disclosure obligations remain in place.
Doseology Sciences (DOSEF) received a management cease trade order after missing the October 28, 2026 deadline for its annual filings.
The overdue documents cover the year ended June 30, 2026 and include audited financial statements, management's discussion and analysis, and related certifications. Trading in common shares may continue for persons other than insiders and employees. The company expects its auditor to need approximately two additional weeks and anticipates filing on or before November 15, 2026. Doseology will issue bi-weekly default status reports while the filing default continues.
Doseology Sciences (DOSEF) announced that Larry Latowsky has resigned as a company director, with the resignation effective immediately.
Doseology Sciences (DOSEF) appointed Kareem Baalbaki as interim CEO, interim CFO and director, and Jeremy Wright as a director. Chris Jackson resigned as CEO, and Chris Cherry resigned as CFO. Baalbaki has more than ten years of operations and supply chain experience and previously served as Chief Supply Chain Officer at Revive Superfoods. Wright, a CPA and CMA, is CFO of Avant Brands and formerly served as CFO of Alpha Cognition.
Doseology also completed a shares-for-debt settlement with a former consultant, issuing 75,268 common shares at a deemed price of $0.18 per share to settle $13,548.39 in accrued share-based consulting compensation. The settlement follows its September 23, 2026 announcement. The issued shares are subject to applicable resale restrictions under Canadian securities laws.
Doseology Sciences (DOSEF) proposed issuing 75,268 shares to settle former consultant compensation and announced a director’s resignation.
The shares have a deemed price of $0.18 each and would settle $13,548.39 in accrued share-based consulting compensation. Doseology anticipates completing the settlement on or about September 30, 2026, subject to applicable corporate, securities law and CSE requirements. Daniel Vice resigned as a director effective September 17, 2026.
Doseology (OTCQB: DOSEF) arranged a non-brokered private placement to raise up to $2.0M by issuing up to 3,225,806 Units at $0.62 per Unit. Each Unit includes one share and one two-year warrant exercisable at $1.00, subject to acceleration.
The company said net proceeds will fund commercialization of its oral stimulant pouch platform: production equipment, pilot manufacturing facility, initial runs, inventory, marketing, distribution expansion and general working capital. Closing is subject to CSE approval and securities hold/resale restrictions.
Doseology (OTCQB: DOSEF) commenced trading on the OTCQB Venture Market on March 11, 2026, expanding U.S. investor access and aligning the company with higher reporting and governance standards. The company appointed Larry Latowsky as Executive Chairman and disclosed pre-funded warrant issuances tied to its Feed That Brain acquisition.
Doseology issued 75,000 pre-funded warrants at a deemed $1.00 price, with additional $75,000 issuances due at the one-year and 18-month anniversaries; the four-month hold on the initial warrants expires July 11, 2026.
Doseology (OTCQB: DOSEF) launched Feed That Brain® Energy Pouches in a U.S. direct-to-consumer pilot on March 4, 2026. The nicotine-free, caffeine-based oral pouches are available exclusively at feedthatbrain.com and Amazon.com, designed for portion-controlled, discreet stimulation without sugar, smoke, or liquid.
The pilot will evaluate consumer adoption, usage frequency, and repeat purchase behaviour to validate oral pouch delivery as a scalable stimulant platform. The company also granted 140,000 RSUs (vesting monthly over 36 months) and 210,000 PSUs tied to performance milestones.
Doseology (PINK:DOSEF; CSE:MOOD) appointed Larry Latowsky as director and Executive Chairman, effective February 18, 2026. The company granted 4,000 RSUs (36-month monthly vesting) and 6,000 PSUs tied to performance milestones. Doseology positions itself to scale precision oral stimulant delivery with strengthened governance and capital-markets expertise.
Latowsky brings pharmacy retail, manufacturing, and deal experience, including leadership roles at Katz Group and involvement in a ~C$3 billion transaction with McKesson.
Doseology (PINK: DOSEF) has begun a pilot production run of non‑nicotine, caffeine‑based energy pouches under its wholly owned Feed That Brain brand. The pilot is a limited direct‑to‑consumer initiative launching in the coming weeks and is exploratory, not a commercial roll‑out.
The pouch format emphasizes portioned, non‑liquid caffeine delivery focused on consistency, predictability, and user control. Doseology positions the pilot to gather product testing, consumer feedback, and operational learnings to inform future formulation, delivery design, and commercialization decisions.